Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Authors: Jeffrey L. Lennox, Raphael J. Landovitz, Heather J. Ribaudo
Journal: Annals of Internal Medicine (2015)

Letters17 March 2015Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1Jeffrey L. Lennox, MD, Raphael J. Landovitz, MD, MSc, and Heather J. Ribaudo, PhDJeffrey L. Lennox, MDFrom Emory University School of Medicine, Atlanta, Georgia; Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, California; and Harvard School of Public Health, Boston, Massachusetts., Raphael J. Landovitz, MD, MScFrom Emory University School of Medicine, Atlanta, Georgia; Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, California; and Harvard School of Public Health, Boston, Massachusetts., and Heather J. Ribaudo, PhDFrom Emory University School of Medicine, Atlanta, Georgia; Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, California; and Harvard School of Public Health, Boston, Massachusetts.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L15-5066-3 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Stephan proposes a potential bias against ritonavir-boosted atazanavir due to the necessity to reimburse ritonavir copayments. He also suggests that efforts to ensure adequate representation of women may have enriched the study for impoverished participants predisposed to discontinue ritonavir-containing regimens to avoid costs. We did not target any particular socioeconomic subgroup of women for enrollment nor have we suggested that we did so. The potential biases associated with ritonavir use during the study were anticipated and addressed during trial design. As noted in the article, all participants not receiving ritonavir from a federal insurance program were reimbursed ...References1. Choe PG, Park WB, Song KY, Bang JH, Kim ES, Park SW, et al. Effect of ritonavir-boosting on atazanavir discontinuation due to jaundice in HIV-infected Koreans. Infect Chemother. 2012;44:175-9. CrossrefGoogle Scholar2. Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB, et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis. 2010;51:101-6. [PMID: 20504240] doi:10.1086/653427 CrossrefMedlineGoogle Scholar3. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999;9:591-9. [PMID: 10591539] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Emory University School of Medicine, Atlanta, Georgia; Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, California; and Harvard School of Public Health, Boston, Massachusetts.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1084. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEfficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , Heather J. Ribaudo , Ighovwerha Ofotokun , Lumine H. Na , Catherine Godfrey , Daniel R. Kuritzkes , Manish Sagar , Todd T. Brown , Susan E. Cohn , Grace A. McComsey , Francesca Aweeka , Carl J. Fichtenbaum , Rachel M. Presti , Susan L. Koletar , David W. Haas , Kristine B. Patterson , Constance A. Benson , Bryan P. Baugh , Randi Y. Leavitt , James F. Rooney , Daniel Seekins , Judith S. Currier , and Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Jeffrey L. Lennox , Raphael J. Landovitz , Heather J. Ribaudo , Ighovwerha Ofotokun , Lumine H. Na , Catherine Godfrey , Daniel R. Kuritzkes , Manish Sagar , Todd T. Brown , Susan E. Cohn , Grace A. McComsey , Francesca Aweeka , Carl J. Fichtenbaum , Rachel M. Presti , Susan L. Koletar , David W. Haas , Kristine B. Patterson , Constance A. Benson , Bryan P. Baugh , Randi Y. Leavitt , James F. Rooney , Daniel Seekins , Judith S. Currier , and Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Christoph Stephan Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Giuseppe Lapadula and Andrea Gori Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Christoph Stephan Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 Giuseppe Lapadula and Andrea Gori Metrics Cited ByAssociation Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIVHIV 17 March 2015Volume 162, Issue 6Page: 461-462KeywordsCohort studiesDisclosureHIV-1NucleosidesObservational studiesProtease inhibitorsReverse transcriptase inhibitorsSafetySafety studiesToxicity ePublished: 17 March 2015 Issue Published: 17 March 2015 CopyrightCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...